In an­oth­er PhI­II, Al­bert Bourla con­tin­ues to build case for a once-flopped GHD drug

A growth hor­mone treat­ment that’s seen a tur­bu­lent path may fi­nal­ly be reach­ing the light at the end of the tun­nel.

Pfiz­er and Op­ko Health an­nounced Thurs­day morn­ing that their once-week­ly so­ma­tro­gon met its pri­ma­ry end­point in a Phase III study, beat­ing out Pfiz­er’s old dai­ly Genotropin (so­ma­t­ropin) ther­a­py in the per­cep­tion of treat­ment bur­den. The news fol­lows pos­i­tive Phase III da­ta from 2019 show­ing clin­i­cal ben­e­fits, as well as a pre­vi­ous flop near the end of 2016 mea­sur­ing the pro­gram against a sug­ar pill.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER